Although a direct comparison between 18F-olaparib (this work) and other radiolabeled PARP imaging agents is hampered by the different model systems that are being used, the main advantage of 18F-olaparib is its relatively high tumor uptake, a good contrast between PARP-expressing tumors and non–PARP-expressing tumors, and fast tumor uptake kinetics. This evidence concerns the gene PARP1 and neoplasm.